NCT01190930
Clinical Trial Information
Trial Number: NCT01190930 (ClinicalTrials.gov)
Disease Type:
- Hematopoietic Neoplasm/Leukemia - Acute Lymphoblastic Leukemia
- Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma
Trial Title:
Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)
Study ID:
AALL0932
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT01190930-D4 | NCT01190930-D4 Dataset Description: There are 2 data submissions (NCT01190930-D3, and -D4) for PMID 36966262. This dataset, NCT01190930-D4, provides the information of targeted adverse events presented in LR randomized patients by treatment arm in Supplementary Table 5. The data cutoff is 06/30/2019. |
| NCT01190930-D3 | D3: NCT01190930-D3 Dataset Description: There are 2 data submissions (NCT01190930-D3, and -D4) for PMID 36966262. This dataset, NCT01190930-D3, provides the information presented in Figure 1 of consort diagram of patient enrollment, Table 1 of B-ALL Low-Risk patients and LR randomly assigned patients characteristics, and Figure 2 of Disease-free survival / Overall survival analysis. It provides information of events with sites of relapses for LR randomization arm, also information of favorable genetics of LR patients. There is one row for each patient enrolled. The data cutoff is 06/30/2019. |
| NCT01190930-D2 | There are 2 data submissions (NCT01190930-D1, and -D2) for PMID 33411585. This dataset, NCT01190930-D2, contains information on targeted adverse event for Induction, AR Postinduction Premaintenance and AR Maintenance, and AR Maintenance by treatment arm presented in Tables A6 and A7. The data cutoff is 06/30/2019. |
| NCT01190930-D1 | There are 2 data submissions (NCT01190930-D1, and -D2) for PMID 33411585. This dataset, NCT01190930-D1, contains the information on patient enrollment, patient characteristics, event-free survival/disease-free survival/overall survival analysis, cumulative incidence of relapse, SMN and death, induction death, induction failure, and sites of relapses by pulse frequency, oral methotrexate dose and AR maintenance arm presented in Figures 2, 3, 4, A1, A2, A3 and Tables 2, 3, A5. There is one row for each patient enrolled. The data cutoff is 06/30/2019. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®